摘要
高级别胶质瘤(HGG)通常具有严重预后不良反应,在过去十年的治疗过程中引入烷基化剂替莫唑胺可适度改善。对MGMT(O-6甲基鸟嘌呤DNA-甲基转移酶)启动子甲基化状态为患者化疗反应最有效的预测及预后因素之一。例如,评估MGMT启动子状态的分子方法不规范。因此,我们开发了基于甲基化特异性-PCR的荧光毛细管凝胶电泳技术。 这种技术可进行甲基化和未甲基化的等位基因间相对比的半定量估计。在178HGG初诊成人患者中进行了功效和技术准确度的评估,并进行了均匀治疗的回顾性研究。首先,我们分析了MGMT启动子甲基化在不同的分界点生存的影响因素,我们进一步研究成人HGGs中甲基化和未甲基化的等位基因的不同比例与其他知名预后分子因素的关联性。这种方法可验证我们的技术非常灵敏(检测低甲基化百分比,<5%),说明其在新鲜冷冻及FFPE样品中检测肿瘤内的异质性是可行的。
关键词: 成体,高级别胶质瘤,PCR甲基化特异性,肿瘤异质性。
Current Cancer Drug Targets
Title:An Innovative Fluorescent Semi-quantitative Methylation-specific PCR Method for the Determination of MGMT Promoter Methylation is Reflecting Intra-tumor Heterogeneity
Volume: 15 Issue: 7
Author(s): Aurelia Nguyen, Michele Legrain, Georges Noel, Andres Coca, Nicolos Meyer(EA), Roland Schott, Christelle Lasthaus and Marie Pierrette Chenard, Marie Pierre Gaub, Jean Marc Lessinger, Dominique Guenot and Natacha Entz-Werle
Affiliation:
关键词: 成体,高级别胶质瘤,PCR甲基化特异性,肿瘤异质性。
摘要: High grade gliomas (HGG) are usually associated with a very dismal prognosis, which was moderately improving in the last decade with the introduction of the alkylating agent temozolomide in their treatment. The methylation status of MGMT (O6 methylguanine DNA-methyltransferase) promoter is one of the strongest predictive and prognostic factors for the patient chemoresponse. For instance, the molecular method of assessment for MGMT promoter status is not standardized. In this background, we developed a fluorescent capillary gel electrophoresis-based methylation specific-PCR.
This technique allowed a semi-quantitative estimate of the relative ratio between methylated and unmethylated alleles. The efficacy and accuracy of the technique was assessed in a retrospective cohort of 178 newly diagnosed adult HGGs, who were homogeneously treated. First, we analyzed the impact on survival of different cut-off points in the MGMT promoter methylation and, to go further, we correlated these different rates to other well-known prognostic molecular factors involved in adult HGGs. This strategy allowed to validate our technique as a very sensitive technique (detection of a low methylation percentage, < 5%), which was feasible in fresh-frozen as well as in FFPE samples and had the propensity to detect intra-tumor heterogeneity.
This technique identified a new sub-group of anaplastic oligodendrogliomas or oligoastrocytomas defined by a minor methylation and a worse outcome and, therefore, will help to substratify accurately into more homogeneous subgroups of methylated tumors.
Export Options
About this article
Cite this article as:
Aurelia Nguyen, Michele Legrain, Georges Noel, Andres Coca, Nicolos Meyer(EA), Roland Schott, Christelle Lasthaus and Marie Pierrette Chenard, Marie Pierre Gaub, Jean Marc Lessinger, Dominique Guenot and Natacha Entz-Werle , An Innovative Fluorescent Semi-quantitative Methylation-specific PCR Method for the Determination of MGMT Promoter Methylation is Reflecting Intra-tumor Heterogeneity, Current Cancer Drug Targets 2015; 15 (7) . https://dx.doi.org/10.2174/1568009615666150629130139
DOI https://dx.doi.org/10.2174/1568009615666150629130139 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Cancer Stem Cells and Non-Stem Cancer Cells: The Potential of Lipid- Based Nanoparticles
Current Pharmaceutical Design Application of Molecular Imaging Technologies in Antitumor Drug Development and Therapy
Current Pharmaceutical Design microRNAs as Anti-Cancer Therapy
Current Pharmaceutical Design Metabolic Dysfunction in Alzheimers Disease and Related Neurodegenerative Disorders
Current Alzheimer Research Development and Clinical Application of Peptide-Based Radiopharmaceuticals
Current Pharmaceutical Design Peroxisome Proliferator Activated Receptor α Ligands as Anticancer Drugs Targeting Mitochondrial Metabolism
Current Pharmaceutical Biotechnology Blood-Brain Barrier Integrity and Glial Support: Mechanisms that can be Targeted for Novel Therapeutic Approaches in Stroke
Current Pharmaceutical Design Novel Fluorine Boron Hybrid Complex as Potential Antiproliferative Drugs on Colorectal Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry The Emerging Role of Stereotactic Radiosurgery in the Treatment of Glioblastoma Multiforme
Current Radiopharmaceuticals Upregulation of Focal Adhesion Kinase by 14-3-3ε via NFκB Activation in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors
Current Cancer Drug Targets Matching Chelators to Radiometals for Positron Emission Tomography Imaging- Guided Targeted Drug Delivery
Current Drug Targets Overview of the Structure and Function of Protein Kinases
Current Enzyme Inhibition Endocannabinoids and Their Receptors: Physiology, Pathology and Pharmacology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Functional Evaluation of Imatinib mesylate in Hepatocellular Carcinoma Cells
Recent Patents on Biomarkers Carbonic Anhydrase IX as a Target for Designing Novel Anticancer Drugs
Current Medicinal Chemistry Synthesis and Biological Activities of Organotin(IV) Complexes as Antitumoral and Antimicrobial Agents. A Review
Mini-Reviews in Medicinal Chemistry Immune Checkpoint Inhibitors: Basics and Challenges
Current Medicinal Chemistry Death Receptor Signaling in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Role of Glioma-associated GLI1 Oncogene in Carcinogenesis and Cancertargeted Therapy
Current Cancer Drug Targets